Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2006-11-13
2010-12-07
Gussow, Anne M. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387100, C530S388100, C530S388220, C530S391100, C424S130100, C424S133100, C424S143100, C424S178100
Reexamination Certificate
active
07847068
ABSTRACT:
The present invention includes fully human, neutralizing, monoclonal antibodies against human Insulin-like Growth Factor Receptor-I (IGFR1). The antibodies are useful for treating or preventing cancer in a subject. Also included are methods of using and producing the antibodies of the invention.
REFERENCES:
patent: 4543439 (1985-09-01), Frackelton, Jr. et al.
patent: 4604463 (1986-08-01), Miyasaka et al.
patent: 4659516 (1987-04-01), Bowler et al.
patent: 5198340 (1993-03-01), Mukku
patent: 5260291 (1993-11-01), Lunt et al.
patent: 5262308 (1993-11-01), Baserga
patent: 5362718 (1994-11-01), Skotnicki et al.
patent: 5719148 (1998-02-01), Bishop et al.
patent: 5942412 (1999-08-01), Prager et al.
patent: 5958708 (1999-09-01), Hardman et al.
patent: 5958872 (1999-09-01), O'Connor et al.
patent: 5977307 (1999-11-01), Friden et al.
patent: 6022711 (2000-02-01), Cunningham et al.
patent: 6084085 (2000-07-01), Baserga et al.
patent: 6217866 (2001-04-01), Schlessinger et al.
patent: 6294330 (2001-09-01), Michnick et al.
patent: 6300129 (2001-10-01), Lonberg et al.
patent: 6316462 (2001-11-01), Bishop et al.
patent: 6333031 (2001-12-01), Olsson et al.
patent: 6346390 (2002-02-01), Olsson et al.
patent: 6372250 (2002-04-01), Pardridge
patent: 6403569 (2002-06-01), Achterrath
patent: 6537988 (2003-03-01), Lee
patent: 6645775 (2003-11-01), Clark et al.
patent: 6774122 (2004-08-01), Evans et al.
patent: 6794370 (2004-09-01), Achterrath
patent: 6875432 (2005-04-01), Liu et al.
patent: 6884879 (2005-04-01), Baca et al.
patent: 7037498 (2006-05-01), Cohen et al.
patent: 7060269 (2006-06-01), Baca et al.
patent: 7169901 (2007-01-01), Baca et al.
patent: 7217796 (2007-05-01), Wang et al.
patent: 7235576 (2007-06-01), Riedl et al.
patent: 7297334 (2007-11-01), Baca et al.
patent: 7326567 (2008-02-01), Saha
patent: 7375193 (2008-05-01), Baca et al.
patent: 2002/0022023 (2002-02-01), Ullrich et al.
patent: 2002/0025313 (2002-02-01), Micklus et al.
patent: 2002/0107187 (2002-08-01), Kingston et al.
patent: 2002/0132275 (2002-09-01), Fidler et al.
patent: 2002/0155095 (2002-10-01), Nagabhushan et al.
patent: 2002/0164333 (2002-11-01), Nemerow et al.
patent: 2002/0169116 (2002-11-01), Kingston et al.
patent: 2002/0187925 (2002-12-01), Kingston et al.
patent: 2002/0197262 (2002-12-01), Hasan et al.
patent: 2003/0021780 (2003-01-01), Smith et al.
patent: 2003/0031658 (2003-02-01), Brodt et al.
patent: 2003/0045676 (2003-03-01), Kingston et al.
patent: 2003/0087342 (2003-05-01), Mermod et al.
patent: 2003/0088061 (2003-05-01), Staunton
patent: 2003/0092631 (2003-05-01), Deshayes et al.
patent: 2003/0138430 (2003-07-01), Stimmel et al.
patent: 2003/0165502 (2003-09-01), Fujita-Yamaguchi
patent: 2003/0195147 (2003-10-01), Pillutla et al.
patent: 2003/0235582 (2003-12-01), Singh et al.
patent: 2003/0236190 (2003-12-01), Pillutla et al.
patent: 2004/0009154 (2004-01-01), Khan et al.
patent: 2004/0009906 (2004-01-01), Kakkis et al.
patent: 2004/0018191 (2004-01-01), Wang et al.
patent: 2004/0023887 (2004-02-01), Pillutla et al.
patent: 2004/0038394 (2004-02-01), Kim et al.
patent: 2004/0047835 (2004-03-01), Bianco
patent: 2004/0057950 (2004-03-01), Waksal et al.
patent: 2004/0086503 (2004-05-01), Cohen et al.
patent: 2004/0086511 (2004-05-01), Zack et al.
patent: 2004/0102360 (2004-05-01), Barnett et al.
patent: 2004/0116330 (2004-06-01), Naito et al.
patent: 2004/0142381 (2004-07-01), Hubbard et al.
patent: 2004/0166580 (2004-08-01), Plaetinck et al.
patent: 2004/0202651 (2004-10-01), Cohen et al.
patent: 2004/0228859 (2004-11-01), Graus et al.
patent: 2004/0265307 (2004-12-01), Singh et al.
patent: 2005/0008642 (2005-01-01), Graus et al.
patent: 2005/0009988 (2005-01-01), Harris et al.
patent: 2005/0048050 (2005-03-01), Fujita-Yamaguchi
patent: 2005/0059672 (2005-03-01), Zhu et al.
patent: 2005/0069539 (2005-03-01), Cohen et al.
patent: 2005/0084906 (2005-04-01), Goetsch et al.
patent: 2005/0136063 (2005-06-01), Wang et al.
patent: 2005/0169933 (2005-08-01), Steeves et al.
patent: 2005/0176099 (2005-08-01), Saha
patent: 2005/0186203 (2005-08-01), Singh et al.
patent: 2005/0244408 (2005-11-01), Cohen et al.
patent: 2005/0249728 (2005-11-01), Singh et al.
patent: 2005/0249730 (2005-11-01), Goetsch et al.
patent: 2005/0272637 (2005-12-01), Clinton et al.
patent: 2005/0272755 (2005-12-01), Denis et al.
patent: 2005/0281812 (2005-12-01), Cohen et al.
patent: 2006/0018910 (2006-01-01), Gualberto et al.
patent: 2006/0140960 (2006-06-01), Wang et al.
patent: 2006/0205810 (2006-09-01), Zong et al.
patent: 2006/0233804 (2006-10-01), Dehayes et al.
patent: 2006/0233814 (2006-10-01), Goldmakher
patent: 2006/0286103 (2006-12-01), Kolhe et al.
patent: 2007/0059241 (2007-03-01), Wang et al.
patent: 2007/0059305 (2007-03-01), Wang et al.
patent: 2008/0014197 (2008-01-01), Wang et al.
patent: 2008/0112888 (2008-05-01), Wang
patent: 197 19 001 C 2 (2001-05-01), None
patent: 2834900 (2003-07-01), None
patent: 2834990 (2003-07-01), None
patent: 2834991 (2003-07-01), None
patent: WO 91/04014 (1991-04-01), None
patent: WO 91/14438 (1991-10-01), None
patent: WO 97/44352 (1997-11-01), None
patent: WO98/17801 (1998-04-01), None
patent: WO 98/22092 (1998-05-01), None
patent: WO 98/45427 (1998-10-01), None
patent: WO 99/25378 (1999-05-01), None
patent: WO 99/28347 (1999-06-01), None
patent: WO 99/42127 (1999-08-01), None
patent: WO 99/60023 (1999-11-01), None
patent: WO 00/22130 (2000-04-01), None
patent: WO 00/50067 (2000-08-01), None
patent: WO 00/69454 (2000-11-01), None
patent: WO 00/69454 (2000-11-01), None
patent: WO 01/07084 (2001-02-01), None
patent: WO 01/30964 (2001-05-01), None
patent: WO 01/36632 (2001-05-01), None
patent: WO 01/70268 (2001-09-01), None
patent: WO 01/70930 (2001-09-01), None
patent: WO 01/72771 (2001-10-01), None
patent: WO 01/75064 (2001-10-01), None
patent: WO 02/04522 (2002-01-01), None
patent: WO 02/07783 (2002-01-01), None
patent: WO 02/27017 (2002-04-01), None
patent: WO 02/31500 (2002-04-01), None
patent: WO 02/43758 (2002-06-01), None
patent: WO 02/053596 (2002-07-01), None
patent: WO 02/054066 (2002-07-01), None
patent: WO 02/072780 (2002-09-01), None
patent: WO 2004/087756 (2002-10-01), None
patent: WO 02/088752 (2002-11-01), None
patent: WO 02/092599 (2002-11-01), None
patent: WO 02/102854 (2002-12-01), None
patent: WO 02/102972 (2002-12-01), None
patent: WO 02/102973 (2002-12-01), None
patent: WO 03/000928 (2003-01-01), None
patent: WO 03/014696 (2003-02-01), None
patent: WO 03/027246 (2003-04-01), None
patent: WO 03/039538 (2003-05-01), None
patent: WO 03/059951 (2003-07-01), None
patent: WO 03/088910 (2003-10-01), None
patent: WO03/100059 (2003-12-01), None
patent: WO 03/106621 (2003-12-01), None
patent: WO 2004/030625 (2004-04-01), None
patent: WO 2004/030627 (2004-04-01), None
patent: WO 2004/056865 (2004-07-01), None
patent: WO 2004/071529 (2004-08-01), None
patent: WO 2004/083248 (2004-09-01), None
patent: WO2004/096224 (2004-11-01), None
patent: WO 2005/005635 (2005-01-01), None
patent: WO 2005/016967 (2005-02-01), None
patent: WO 2005/016970 (2005-02-01), None
patent: WO 2005/016970 (2005-02-01), None
patent: WO2005/052005 (2005-06-01), None
patent: WO 2005/061541 (2005-07-01), None
patent: WO2005/117980 (2005-12-01), None
patent: WO2006/013472 (2006-02-01), None
patent: WO2006/020258 (2006-02-01), None
patent: WO 2006/069202 (2006-06-01), None
patent: WO2007/093008 (2007-08-01), None
Green, Larry L.; “Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies”; Journal of Immunological Methods; 231:11-23 (1999).
Stefania Benini et al., Inhibition of Insulin-like Growth Factor I Receptor Increases the Antitumor Activity of Doxorubicin and Vincristine Against Ewing's Sarcoma Cells, Clinical Cancer Research, vol. 7, 1790-1797, Jun. 2001.
V.M. Macaulay, Insulin-like Growth Factors and Cancer, Br. J. Cancer, 65, 311-320, 1992.
Xiangdang Liu et al., Inhibition of Insulin-like Growth Factor I Receptor Expression in Neuroblastoma Cells Induces the Regression of Established Tumor
Brams Peter
Feingersh Diane
Greenberg Robert
Hailey Judith
Pachter Jonathan A.
Gussow Anne M.
Schering Corporation
LandOfFree
Neutralizing human anti-IGFR antibody does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Neutralizing human anti-IGFR antibody, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Neutralizing human anti-IGFR antibody will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4221196